Aventis Pharma S.a.

Aventis Behring Gmbh

Rhone-poulenc Rorer S.a.

Novozymes Biopharma UK Limited

Other

Novozymes Biopharma Dk A/s

Institut National De La Sante Et De La Recherche Medicale

Alain Fournier

Patrice Yeh

Reinhard Fleer

Jean-Dominique Guitton

Gérard Jung

Laurent Pradier

Alexis Brice

Isabelle Maury

Olga Corti

Catherine Prades

Luc Mercken

Marie-Françoise Rosier-Montus

Isabelle Arnould-Reguigne

Thomas Rooney

Jean-Francois Mayaux

Christophe Marcireau

Didier Branellec

Jean-Francois Riou

Hana Koutnikova

Cornelia Hampe

H&eacute;l&egrave;ne Goulaouic

G&eacute;rard Jung

Qing Zhou-Liu

Han Koutnikova

Francine Desanlis-Cremond

Abderrahim Mahfoudi

Sabine Strahl-Bolsinger

Widmar Tanner

Gerard Jung

The present invention relates to novel compounds and their uses, in particular their pharmaceutical or diagnostic uses or their use as pharmacological targets. More particularly, the present invention relates to a novel protein, referred to as PAP1, as well as to novel peptides and compounds which are capable of modulating, at least partially, the activity of parkin.

Nucleic acids encoding a human PAP1 polypeptide

Biologically active polypeptides comprising a therapeutically active polypeptide fused to human serum albumin or a variant of human serum albumin, methods for preparation, nucleotide sequences encoding such fusion polypeptides, expression cassettes comprising such nucleotide sequences, self-replicating plasmids containing such expression cassettes, and pharmaceutical compositions containing fusion polypeptides.

Methods of treating using hormone-albumin fusion proteins

The present invention concerns DNA sequences from the K. lactis PGK gene having transcriptional promoter activity. to expression vectors comprising these sequences and to their use for the production of proteins.

Yeast promoter and use thereof

Biologically active polypeptides comprising a therapeutically active polypeptide fused to human serum albumin or a variant thereof, methods for the preparation thereof, nucleotide sequences encoding such fusion polypeptides, expression cassettes comprising such nucleotide sequences, self-replicating plasmids containing such expression cassettes, and pharmaceutical compositions containing said fusion polypeptides.

Methods of treatment with interferson and albumin fusion protein

The invention includes biologically active polypeptides comprising a therapeutically active polypeptide fused to human serum albumin or a variant of human serum albumin, methods for the preparation of such fusion polypeptides, nucleotide sequences encoding such fusion polypeptides, expression cassettes comprising such nucleotide sequences, self-replicating plasmids containing such expression cassettes, and pharmaceutical compositions containing such fusion polypeptides.

Fusion polypeptides of human serum albumin and a therapeutically active polypeptide

Compositions which can be used for regulating the activity of parkin

Insulin and albumin fusion protein

Interleukin and albumin fusion protein

The present invention relates to a method for determining the ability of a compound to modify the interaction between parkin and the pprotein, and in particular to a method for screening for or detecting compounds intended for the prevention and/or treatment of neurodegenerative pathological conditions. The present inventions also relates to compounds identified in the above screening method.

Method for determining the ability of a compound to modify the interaction between parkin and the p38 protein

Hormone and albumin fusion protein

G-CSF and albumin fusion protein

Methods of treatment with erythropoietin and albumin fusion protein

Erythropoietin and albumin fusion protein, nucleic acids, and methods thereof

Interferon and albumin fusion protein

The present invention relates to novel compounds and their pharmaceutical or diagnostic use, or use as a pharmacological target. More particularly, the present invention describes the identification of partners of the FE65 protein and the use of these partners, or of any compound which is capable of modulating, at least partially, their interaction with FE65, for regulating the activity of FE65, and in particular the phenomenon of intracellular transport or of endocytosis of the APP.

FEBP1 protein vector host cells and method for making FEBP1 protein

Growing community of inventors

Chatenay Malabry, France

Alain Fournier